# US 2014/0154291 A1 · Inhibition of trem receptor signaling with peptide variants > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0154291 A1 - Document ID: US20140154291A1 - Status: Published application - Kind: A1 - Application number: 13/941,445 - Filed: 2013-07-12 - Published: 2014-06-05 - Earliest claimed: 2009-10-13 - Assignees: Signablok, Inc. - Inventors: Alexander B. Sigalov - Web page: https://patentgrep.com/patent/US20140154291A1 ## CPC - A61K 38/03: Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof - A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system - A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents - A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis - A61P 17/00: Drugs for dermatological disorders - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 19/04: for non-specific disorders of the connective tissue - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 35/00: Antineoplastic agents - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) - C07K 14/001: {by chemical synthesis} - C07K 14/70503: {Immunoglobulin superfamily} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices). ## Claims ### Claim at position 1 1-29. (canceled) ### Claim 30 A composition comprising a peptide having a formula consisting of R1-G-X1-X2-L-S-X3-X4-L-V-X5-X6-X7-X8-X9-X10-R2, wherein: R1 is absent or is selected from the group consisting of N-terminal sugar conjugate and N-terminal lipid conjugate; X1 is selected from the group consisting of Gly, Cys, Arg, Lys and H is; X2 is selected from the group consisting of Leu, Phe, and Ile; X3 is selected from the group consisting of Arg, Lys and H is; X4 is selected from the group consisting of Ser and Thr; X5 is selected from the group consisting of Phe, Arg, Lys and H is; X6 is absent or is selected from the group consisting of Ser, Leu and Ile; X7 is absent or is selected from the group consisting of Val, Ile, Leu and Gly; X8 is absent or is selected from the group consisting of Leu, Phe, and Ala; X9 is absent or is selected from the group consisting of Leu, Phe, and Ala; X10 is absent or is selected from the group consisting of Leu, Phe, and Ala; and R2 is absent or is C-terminal lipid conjugate. ### Claim 31 (depends on 30) The composition of claim 30, wherein said N-terminal sugar conjugate is 1-amino-glucose succinate. ### Claim 32 (depends on 30) The composition of claim 30, wherein said N-terminal lipid conjugate is selected from the group consisting of 2-aminododecanoate and myristoylate conjugates. ### Claim 33 (depends on 30) The composition of claim 30, wherein said C-terminal lipid conjugate is selected from the group consisting of Gly-Tris-monopalmitate, Gly-Tris-dipalmitate and Gly-Tris-tripalmitate conjugates. ### Claim 34 (depends on 30) The composition of claim 30, wherein the peptide is attached to a carrier molecule. ### Claim 35 (depends on 30) The composition of claim 30, wherein the peptide is conjugated at a free amine group with a polyalkylene glycol. ### Claim 36 (depends on 35) The composition of claim 35, wherein the said polyalkylene glycol is polyethylene glycol. ### Claim 37 (depends on 30) The composition of claim 30, wherein one or more amino acid is a D-amino acid. ### Claim 38 (depends on 30) The composition of claim 30, wherein said amino acid sequence further comprises at least one amino acid selected from the group consisting of an L-amino acid and a D-amino acid. ### Claim 39 (depends on 30) The composition of claim 30, wherein said peptide is a cyclic peptide. ### Claim 40 (depends on 30) The composition of claim 30, wherein said peptide is a cyclic dimer peptide. ### Claim 41 (depends on 30) The composition of claim 30, wherein said peptide is a dimer peptide. ### Claim 42 (depends on 30) A method of treating a subject suffering from a disease or condition in which myeloid cells are involved or recruited, said method comprising administering to a subject a therapeutically effective amount of the composition of claim 30 so as to treat in the said subject a disease or condition, in which myeloid cells are involved or recruited. ### Claim 43 (depends on 30, 42) The method of claim 42 comprising: a) providing i) a patient having at least one symptom of a disease or condition in which myeloid cells are involved or recruited; and ii) the composition of claim 30; b) administering said composition to said patient under conditions such that said at least one symptom is reduced. ### Claim 44 (depends on 43) The method of claim 43, wherein said disease or condition in which myeloid cells are involved or recruited is selected from the group comprising sepsis, cancer, inflammatory bowel disease, acute mesenteric ischemia, hemorrhagic shock, arthritis, ankylosing spondylitis, fibromyalgia, lupus, scleroderma, polymyositis, dermatomyositis, polymyalgia rheumatica, bursitis, tendinitis, vasculitis, carpal tunnel syndrome, complex regional pain syndrome, juvenile arthritis, Lyme disease, systemic lupus erythematosus, Kawasaki disease, fibromyalgia, chronic fatigue syndrome, myositis and tissue and organ rejection. ### Claim 45 (depends on 30) A biocompatible medical device comprising a coating, wherein said coating comprises the peptide of claim 30. ### Claim 46 (depends on 45) The device of claim 45, wherein said device is selected from the group consisting of stents, grafts, catheters, endoscopes, atrial/venous fistulas, and cannulae. ### Claim 47 (depends on 45) The device of claim 45, wherein the said coating further comprises a polymer. ### Claim 48 (depends on 47) The device of claim 47, wherein said polymer is selected from the group consisting of phosphorylcholine, polyvinyl pyrrolidone, poly(acrylic acid), poly(vinyl acetamide), poly(propylene glycol), poly(ethylene co-vinyl acetate), poly(n-butyl methacrylate) and poly(styrene-b-isobutylene-b-styrene).